The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or ...

Immunotherapy is the brightest new weapon in fight against cancer. Thank Dr. Steven Rosenberg, who 40 years ago successfully ...

The findings suggest a new drug target that could lead to therapies for deadly metastatic skin cancer ... cells before they ...

Oct. 17, 2024 — Scientists developed a way of using artificial intelligence to check for skin cancer with the AI tool, which was trained on data from 53,601 skin lesions from 25,105 patients ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

"We know how to cure primary tumors—with surgery, and sometimes with chemotherapy and radiation. Metastatic disease ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...

all patients developing positive DTH reactions had a clinical response of complete or partial rejection of metastatic lesions. Patient 2, who did not develop a positive skin reaction after ...

Detection of metastatic disease by imaging is based on lesion size, lesion-to-liver contrast difference, and lesion-to-liver edge definition. [1,16] To maximize the detection of lesions ...

Checkpoint Therapeutics' Unloxcyt wins FDA approval for advanced cSCC, marking the company's entry into the U.S. market, valued over $1 billion annually.